Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer
Ribometrix Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
Ribometrix To Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024
Ribometrix to Present Additional Preclinical Data for eIF4E Program at the San Antonio Breast Cancer Symposium
Ribometrix Announces Lead Program Target and Presentation of Preclinical Data at the International Congress of the Society for Melanoma Research
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
Ribometrix Further Expands Leadership with Appointment of Barclay “Buck” Phillips as Chief Operating Officer and Chief Financial Officer
Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics